ABSTRACT
Aberrant histone acetylation was physiopathologically associated with the development of acute myeloid leukemias (AMLs). Reversal of histone deacetylation by histone deacetylase inhibitor (HDACis) activates a cell death program that allows tumor regression in mouse models of AMLs. We have used several models of PML-RARA-driven acute promyelocytic leukemias (APLs) to analyze the in vivo effects of valproic acid, a well-characterized HDACis. Valproic acid (VPA)-induced rapid tumor regression and sharply prolonged survival. However, discontinuation of treatment was associated to an immediate relapse. In vivo, as well as ex vivo, VPA-induced terminal granulocytic differentiation. Yet, despite full differentiation, leukemia-initiating cell (LIC) activity was actually enhanced by VPA treatment. In contrast to all-trans retinoic acid (ATRA) or arsenic, VPA did not degrade PML-RARA. However, in combination with ATRA, VPA synergized for PML-RARA degradation and LIC eradication in vivo. Our studies indicate that VPA triggers differentiation, but spares LIC activity, further uncouple differentiation from APL clearance and stress the importance of PML-RARA degradation in APL cure.
Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL
Riferimento:
Leukemia. 2012 Jul;26(7):1630-7.
Autori:
Leiva M, Moretti S, Soilihi H, Pallavicini I, Peres L, Mercurio C, Dal Zuffo R, Minucci S, de Thé H.
Fonte:
Leukemia. 2012 Jul;26(7):1630-7.
Anno:
2012
Azione:
In combinazione con l'acido all-trans retinoico (ATRA), l'acido valproico (VPA) e in sinergia con il gene PML (leucemia promielocitica)-RARA (retinoico recettore alfa acido) si induce degradazione ed eradicazione in vivo delle cellule di avvio (LIC) della leucemia acuta promielocitica (APL).
Target:
ATRA-VPA-PML-RARA gene/leucemia acuta promielocitica.
Sostanze:
